factor VIII recombinant
Selected indexed studies
- Recombinant factor VIII: past, present and future of treatment of hemophilia A. (Drugs Today (Barc), 2018) [PMID:29869648]
- Coagulation factor VIII: biological basis of emerging hemophilia A therapies. (Blood, 2024) [PMID:39088776]
- Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies. (Front Immunol, 2020) [PMID:33569066]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Recombinant factor VIII: past, present and future of treatment of hemophilia A. (2018) pubmed
- Coagulation factor VIII: biological basis of emerging hemophilia A therapies. (2024) pubmed
- Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies. (2020) pubmed
- Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. (2002) pubmed
- Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. (2017) pubmed
- Production processes of licensed recombinant factor VIII preparations. (2001) pubmed
- Purified factor VIII. (1995) pubmed
- Efficacy and safety of recombinant factor VIII products in patients with hemophilia A. (2008) pubmed
- A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII. (2009) pubmed
- Acquired hemophilia. (2020) pubmed